ARS Pharmaceuticals Shares Plunge as Neffy Misses July Insurance Wins
Despite the setback, Florida Medicaid coverage begins July 1, the company cut 2026 expenses to $248M, and it remains on track for cash-flow breakeven in 2027.
/ 3 items
#SPRY↓
Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug Approval
Aquestive Therapeutics stock plunges after FDA identifies deficiencies in Anaphylm application, a sublingual film treatment for severe allergic reactions.
ARS Pharmaceuticals Neffy Nasal Spray Approved in Japan
Japan approved neffy (epinephrine nasal spray). This needle-free option treats severe allergies (anaphylaxis) in adults and kids (>15 kg). It's the first in Japan, offering a compact, injection-free alternative. Availability starts late 2025.